Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. And welcome to Invivyd’s First Quarter 2025 Earnings Conference Call. At this time, all participants are in a ...

Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ETCompany ParticipantsKatie Falzone - Senior Vice President, ...

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a ...

AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE:AZTR) reported first quarter 2025 results in a May 13 th  press ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

The rate of AEs among pediatric patients with presumed TB disease was increased for those who received higher vs lower doses of WHO-recommended first-line treatment.

We performed a prospective, randomized, double-blind comparison of rofecoxib and naproxen ... 29 Analyses of 7535 patients in double-blind trials comparing rofecoxib with placebo and other NSAIDs ...

Next Steps: - Complete data analysis - Submit to FDA/CDSCO for additional pivotal trials "Dose optimization is a critical milestone for our broad-spectrum antiviral platform," said David Platt ...

Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify approved uses, the dosage, ...

"The consistency of our results, including 100% viral clearance in prior studies, gives us strong confidence as we prepare for additional clinical trials.” "Dose optimization is a critical ...